Article Abstract

A balancing act for breast cancer? Everolimus for hormone receptor positive patients

Authors: Stephanie B Wheeler, Katherine Reeder-Hayes, Anne-Marie Meyer

Abstract

Recent results from a Phase III randomized trial comparing everolimus [a mammalian target of rapamycin (mTOR) inhibitor] plus exemestane versus placebo plus exemestane provide encouraging evidence of a new option for treatment of advanced, hormone receptor positive (HR+) breast cancer (1). Oral endocrine therapy (ET) is the first line therapeutic strategy of choice for most women with metastatic HR+, Her2 negative breast cancer (2).

Refbacks

  • There are currently no refbacks.